Search
bupropion/naltrexone (Contrave)
FDA approved for treatment of obesity Sept 2014 [2]
Indications:
- obesity
- weight reduction 4.2% better than placebo
Contraindications:
- insomnia is adverse effect, thus relative contraindication
Adverse effects:
- insomnia
Notes:
- clinical trial safety testing halted due to unauthorized release of data compromising study's integrity [3]
- cardiovascular risks still unknown [4]
General
anorexiant (appetite suppressant)
pharmacologic combination
References
- Physician's First Watch, Dec 8, 2010
Massachusetts Medical Society
http://www.jwatch.org
- Astrup A.
Is cardiometabolic risk improved by weight-loss drugs?
Lancet 2010 Aug 21; 376:567
PMID: 20673996
- Nainggolan L
FDA Approves Bupropion/Naltrexone (Contrave) for Obesity.
Medscape: Sppt 10, 2014
http://www.medscape.com/viewarticle/831513
- FDA News Release. September 10, 2014
FDA approves weight-management drug Contrave.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm413896.htm
- Cleveland Clinic News Release. May 12, 2015
Clinical Trial Testing Safety Of Obesity Drug Contrave Halted;
50 Percent Interim Data Released By The Study's Executive
Committee.
http://my.clevelandclinic.org/about-cleveland-clinic/newsroom/releases-videos-newsletters/2015-5-12-clinical-trial-testing-safety-of-obesity-drug-contrave-halted
- Nissen SE, Wolski KE, Prcela L et al
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular
Events in Overweight and Obese Patients With Cardiovascular
Risk Factors: A Randomized Clinical Trial.
JAMA. 2016 Mar 8;315(10):990-1004.
PMID: 26954408
- Sharfstein JM, Psaty BM.
Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion:
A Study Interrupted.
JAMA. 2016 Mar 8;315(10):984-6.
PMID: 26954405
Components
bupropion (Wellbutrin, Wellbutrin SR, Zyban, Aplenzin)
naltrexone (ReVia, Trexan, Vivitrol, Vivitrex)